factors that could predict relapse after stopping anti-viral agents.

StephenW

Aliment Pharmacol Ther 2011; 34: 344–352

Summary
Background  Optimal duration of anti-viral therapy in chronic hepatitis B virus (HBV) infection remains unclear.

Aim  To investigate factors that could predict relapse after stopping anti-viral agents.

Methods  Chronic hepatitis B patients who were treated with anti-viral agents (lamivudine, adefovir, entecavir) and have stopped the treatment were recruited. Anti-viral agents were stopped according to the recommendations of the Asian Pacific Association for the Study of the Liver. Virological relapse was defined as an increase in serum HBV DNA to >1000 copies/mL after discontinuation of treatment.

Results  Eighty-four (69 treatment naïve and 15 lamivudine resistant) patients were eligible for this study. Thirty-seven patients developed virological relapse at 4.3 ± 2.9 (range 1–11) months after discontinuation of therapy. The 1-year cumulative probability of virological relapse was 42% and 47% in HBeAg (hepatitis B e antigen)-positive (n = 41) and HBeAg (hepatitis B e antigen)-negative (n = 43) patients, respectively. On multivariate analysis by Cox proportional hazard model, pre-existing lamivudine resistance, delayed suppression of HBV DNA to undetectable level during anti-viral therapy and to a higher HBsAg (hepatitis B surface antigen) level at the end of treatment were associated with virological relapse. Twelve of the 15 (80%) lamivudine resistant patients developed virological relapse. Among the 11 treatment naïve patients who had HBsAg ≤2 log IU/mL at the end of treatment, 1 (9%) of them had virological relapse.

Conclusions  Treatment cessation among lamivudine resistant patients is associated with high risk of virological relapse. Serum HBsAg level at the end of treatment and rate of HBV DNA suppression can provide supplementary information to guide the timing of stopping anti-viral drugs.                           



(6.合.彩).足球.篮球...各类投注开户下注

第一投注.现金网:招代理年薪10万以上:6668.cc

StephenW

谷歌翻译是不是100％正确，仅供参考，使用。

Aliment药理2011;34：344-352

摘要
背景的抗病毒治疗慢性乙型肝炎病毒（HBV）感染的最佳持续时间仍不明朗。

目的探讨抗病毒药物停药后复发，可以预测的因素。

方法慢性乙型肝炎治疗抗病毒药物（拉米夫定，阿德福韦，恩替卡韦），并已停止治疗的病人被招募。根据亚洲太平洋肝脏研究协会的建议停止抗病毒药物。被定义为血清HBV DNA>1000拷贝/ ml增加停药后病毒学复发。

结果八十四（69天真的治疗和15拉米夫定耐药）患者，这项研究的资格。 37例在4.3±2.9个月（范围1-11）停药后病毒学复发。病毒学复发，1年累积概率为42％和47％在HBeAg（乙肝e抗原）阳性（N= 41）和HBeAg（乙肝e抗原）阴性（N= 43）患者，分别。在多变量Cox比例风险模型，预先存在拉米夫定耐药性，延迟的HBV DNA抑制到检测不到的水平和抗病毒治疗期间较高的乙肝表面抗原（乙肝表面抗原）在治疗结束时的水平分析与病毒学复发。 15（80％）中的12拉米夫定耐药患者开发病毒学复发。其中的11个治疗初治患者曾乙肝表面抗原≤2日志国际单位/毫升，在治疗结束后1（9％），其中有病毒学复发。

结论拉米夫定耐药患者之间的治疗停止与病毒学复发的高风险。在治疗和HBV DNA抑制率结束时的血清HBsAg水平可以提供补充资料，指导何时停止抗病毒的药物。

把握当下

结论：
共84人 (69初治，15拉米耐药)。
37人在停药后4.3 ± 2.9个月期间反弹（反弹标准是dna>1000拷贝/ ml）。
一年反弹率：e抗原阳的42% ，e抗原阴的47% 。
拉米耐药、dna下降缓慢、停药时s抗原高者易复发。
80%拉米耐药患者复发。
11名初治、停药时s抗原少于100 IU/mL 患者中只有1人复发(9%)

。。。还是有复发呀

StephenW

把握当下 发表于 2011-10-17 21:33
结论：
共84人 (69初治，15拉米耐药)。
37人在停药后4.3 ± 2.9个月期间反弹（反弹标准是dna>1000拷贝/ ml ...

"还是有复发呀" - 正确的，因此，停药方针需要研究和改进

StephenW

一般都能 发表于 2011-10-18 06:55
又一拨炒老王剩饭的，也不错。

你说这一个？ - "拉米耐药、dna下降缓慢、停药时s抗原高者易复发。"
什么是老王对血清HBsAg水平的理论?

一般都能

StephenW 发表于 2011-10-18 11:06
你说这一个？ - "拉米耐药、dna下降缓慢、停药时s抗原高者易复发。"
什么是老王对血清HBsAg水平的理论?
...

你好睁眼瞎四蹄！